Fig. 4: Effect of stabilizing mutations on fusogenicity of S protein. | npj Vaccines

Fig. 4: Effect of stabilizing mutations on fusogenicity of S protein.

From: Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

Fig. 4: Effect of stabilizing mutations on fusogenicity of S protein.

a S protein fusogenicity as measured in a cell–cell fusion assay in HEK293 cells by co-transfection of plasmids encoding S protein, ACE2, TMPRSS2, and GFP. b Overlay of GFP and brightfield channels 24 h after transfection, as in the setup of a. The different S protein constructs are indicated; mock is an untransfected monolayer. The scale bar is indicating 200 μm. c Quantitative cell–cell fusion assay setup. d Luciferase signal shown as relative light units (RLU) measured at 4 h post mixing of donor and acceptor cells, as in the setup of c. The error bars represent one s.d.

Back to article page